The Effect of proteolysis-targeting chimera (PROTAC) of EZH2 on high grade Serous ovarian Carcinoma.

被引：0
|
作者：
Hachijo, Ryuta [1 ]
Sone, Kenbun [1 ]
Jonouchi, Yuri [1 ]
Ishizaka, Aya [1 ]
Suzuki, Eri [1 ]
Tsuchimochi, Saki [1 ]
Tanimoto, Saki [1 ]
Toyohara, Yusuke [1 ]
Honjo, Harunori [1 ]
Fukuda, Tomohiko [1 ]
Miyamoto, Yuichiro [1 ]
Mori, Mayuyo [1 ]
Oda, Katsutoshi [2 ]
Hirota, Yasushi [1 ]
Osuga, Yutaka [1 ]
机构：
[1] Univ Tokyo, Dept Obstet & Gynecol, Tokyo, Japan
[2] Univ Tokyo, Dept Clin Genom, Tokyo, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3205
引用
收藏
页码：1685 / 1685
页数：1
相关论文
共 50 条
  • [41] HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma
    Mahajan, Aparna
    Liu, Zhaojian
    Gellert, Lan
    Zou, Xuanyi
    Yang, Guangyu
    Lee, Peng
    Yang, Ximing
    Wei, Jian-Jun
    MODERN PATHOLOGY, 2010, 23 (05) : 673 - 681
  • [42] Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma
    Chen, Ling
    Liu, Xinxin
    Zhang, Jin
    Liu, Yanxia
    Gao, Ang
    Xu, Yanning
    Lin, Yang
    Du, Qiuyue
    Zhu, Zhengmao
    Hu, Yuanjing
    Liu, Yixin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (10): : 4977 - +
  • [43] MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/fl-catenin in serous ovarian cancers
    Sun, Yue
    Wu, Jing
    Dong, Xiaoying
    Zhang, Jingzi
    Meng, Chao
    Liu, Guoyan
    TRANSLATIONAL ONCOLOGY, 2021, 14 (02):
  • [44] Rapid identification and targeting of chemotherapy resistant tumor stem cell clones in ovarian high-grade serous carcinoma
    Zhang, Ting
    Ning, Gang
    Yamamoto, Yusuke
    Howitt, Brooke
    Wang, Xia
    Wilson, Lane
    Hong, Yue
    Khor, Chiea Chuen
    Torti, Suzy
    Brewer, Molly
    Crum, Christopher
    McKeon, Frank
    Xian, Wa
    CANCER RESEARCH, 2015, 75
  • [45] miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma
    Dong, Ruifen
    Liu, Xiaolin
    Zhang, Qing
    Jiang, Zhijun
    Li, Yingwei
    Wei, Yuyan
    Li, Yinuo
    Yang, Qifeng
    Liu, Jinsong
    Wei, Jian-Jun
    Shao, Changshun
    Liu, Zhaojian
    Kong, Beihua
    ONCOTARGET, 2014, 5 (21) : 10816 - 10829
  • [46] Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma
    Xie, Jia
    Barbolina, Maria V.
    CANCERS, 2024, 16 (22)
  • [47] Overexpression of enhancer of zeste homolog 2 (EZH2), focal adhesion kinase (FAK), and pFAK in high grade endometrial carcinoma
    Semaan, A.
    Mert, I.
    Solomon, L.
    Morris, R.
    Munkarah, A.
    Sood, A.
    Ali-Fehmi, R.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S164 - S165
  • [48] The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors
    Altman, Alon D.
    Nelson, Gregg S.
    Ghatage, Prafull
    McIntyre, John B.
    Capper, David
    Chu, Pamela
    Nation, Jill G.
    Karnezis, Anthony N.
    Han, Guangming
    Kalloger, Steve E.
    Koebel, Martin
    MODERN PATHOLOGY, 2013, 26 (09) : 1255 - 1263
  • [49] The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma
    Chesnokov, Mikhail
    Yousif, Abdelrahman
    Chefetz, Ilana
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [50] A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma
    Dong, Fei
    Davineni, Phani K.
    Howitt, Brooke E.
    Beck, Andrew H.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2016, 25 (11) : 1511 - 1516
12345